Clinical trial
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
NCT00093470 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00093470 |
|---|---|
| Title | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission |
| Official title | A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22), CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16, 16)(p13.1 and 17 more |
| Intervention type | Drug, Procedure |
| Interventions | Clinical Observation, Tipifarnib |
| Enrollment | 144 |
| Start date | Aug 18, 2004 |
| Primary completion | Feb 20, 2015 |
| First posted | Oct 8, 2004 |
| Last update posted | Mar 20, 2024 |
| Countries | Israel, Peru, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: